Thelansis

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook Thelansis’s “Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Obstructive Pulmonary Disease (COPD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which e...

  Chronic Obstructive Pulmonary Disease (COPD) is a significant cause of chronic morbidity and mortality throughout the world. Many people suffer from this disease for years and die prematurely from its complications. COPD is the fourth leading cause of death globally, and further increases in its prevalence and mortality can be predicted in the coming decades. Chronic inflammation causes structural changes and narrowing of the small airways. Destruction of the lung parenchyma, also by inflammatory processes, leads to the loss of alveolar attachments to the small airways and decreases lung elastic recoil; in turn, these changes diminish the ability of the airways to remain open during expiration. The airflow limitation is best measured by spirometry, as this is the most widely available, reproducible lung function test. The impact of COPD on an individual patient depends not just on the degree of airflow limitation but also the severity of symptoms. There is only an imperfect relat...